Chronic Obstructive Pulmonary Disease (COPD) is a chronic disease that has many concerns in global health. It is characterized by slowly progressive airway obstruction and causes great difficulties in everyday life due to breathlessness when physically active. The steady decline in lung capacity, often resulting in the deterioration of quality of life, means patients are a burden to health care systems. Current therapies are focused on the management of the clinical symptoms rather than the repair of the damaged lung tissue. There is still a strong need for therapies that target the repair of the cellular damage. The provision of the UC-MSCs within the clinics would represent an entirely new alternative for pulmonary restoration. The use of regenerative medicine Thailand frameworks would allow the creation of more complex, advanced, potential therapies for individuals suffering from respiratory failure.
Traditional COPD Treatments
Advanced chronic obstructive pulmonary disease (COPD) management relies primarily on strong bronchodilators in combination with inhaled corticosteroids. Physicians aim to relax the smooth muscles and mitigate inflammation of the airways. The advanced stages of the disease require many patients to rely on continuous oxygen therapy to avoid the fatal effects of hypoxemia. Planned interventions such as pulmonary rehabilitation (PR) are employed to improve exercise tolerance from intensive training and nutritional support. The conventional therapies have many clinical drawbacks. They are only symptomatic and address the destruction of the tissues in the lungs in a transient manner. Extended systemic reliance on potent corticosteroids becomes burdensome due to the adverse effects of severe osteoporosis and increased vulnerability to respiratory infections. The present pharmacological therapies do not slow the progression of disease as patients are left vulnerable to severe acute episodes. The permanent structural damage to the lungs and the inability of the conventional medical treatments to reverse this destruction shows the urgent need for other therapeutic options in regenerative medicine Thailand.
Figure 1: Traditional Advanced COPD Treatments
Mechanism of UC-MSCs for treat COPD
The therapeutic value of UC-MSCs is based more on the ability to communicate with surrounding cells rather than replacement of injured cells. Upon administration, UC-MSCs display targeted chemotactic migration. This means the multipotent cells are attracted to the site of injury within the pulmonary system. Upon arrival within the damaged pulmonary system in COPD, UC-MSCs have the potential to secrete a range of paracrine factors, and these include anti-inflammatory cytokines and extracellular vesicles. These factors have the ability to alter the pulmonary system microenvironment. Within the pulmonary microenvironment, they have the ability to inhibit hyperactivity of pro-inflammatory alveolar macrophages and promote the proliferation of regulatory T cells. This shift in the microenvironment effectively dampens the impact of advanced pulmonary obstruction and the destructive chronic inflammation that is associated with it. UC-MSCs also have the potential to enhance the secretory activity of endogenous lung progenitor cells, which aids the process of regeneration of the pulmonary system and inhibits the overproduction of matrix metalloproteinases, which destroys the extracellular matrix, thereby preventing further damage of the matrix. These therapeutic cells help to repair lung tissues by creating a favorable environment for biological repair and mitigates the damage of oxidative stress induced by the continuous release of antioxidant enzymes.
Why use UC-MSCs for treatment
The potential of adopting advanced therapeutic intervention employing the use of UC-MSCs in clinical settings over the traditional pharmaceutical solutions have many significant physiologic benefits. Unlike drugs that mask symptoms, these cells target the pathological mechanisms of COPD. Because of the potent immunomodulatory ability of these unique cells, they can reset the hyperactive immune system of the patients that is responsible for the destruction of lung tissues. Through their precise secretion of hepatocyte growth factor and vascular endothelial growth factor, these stem cells facilitate the essential angiogenesis necessary to rebuild the damaged pulmonary vascular capillary bed. The absence of major histocompatibility complex class II surface expression makes these specialized cells hypoimmunogenic. For this reason, complex HLA matching procedures are not necessary, and safe allogenic transplantations can be conducted. This is a significant benefit of these cells for clinical use, making their wide-ranging therapeutic application possible. Additionally, the strong anti-apoptotic properties of these cells shield vulnerable alveolar cells against cell death apoptotic from exposure to toxic cigarette smoke. By directing a thorough regenerative cellular response to chronic inflammation and modifying the structure of the tissue, UC-MSCs represent a better therapeutic option in regenerative medicine Thailand to alter the course of chronic disease.
Figure 2: Therapeutic mechanism of UC-MSCs for COPD
Future Trends in Thailand
Cellular therapies to treat COPD in Southeast Asia has a highly promising clinical future. Thailand has the potential to be at the forefront of this therapy in Southeast Asia through medical tourism and being a regional medical hub. The country has a well-developed scientific infrastructure, including advanced biotechnology laboratory facilities, and skilled bio-medical researchers. The country is beginning to adopt more favorable policies to support advanced cellular therapies and promote rigorous clinical testing. This is allowing local researchers to optimize the isolation and extraction of these cells for use in research. Thailand has a huge diversity of patients across the country which is helpful in clinical research to improve treatment. Strategic partnerships and collaborations between cutting-edge governmental research institutes and focus local medical university hospitals will be vital to move the treatments from research into practical bedside use. Thailand aims to provide innovative treatments for severe COPD using its research on specialized stem cells and regenerative medicine.